Bionano Genomics has secured USD 18 million through a private placement of senior secured convertible debentures due May 24, 2026. Canaccord Genuity represented the company as the placement agent and the financial advisor during the transaction.
The funds are expected to be used to retire the convertible debt financing that was previously entered first in October 2023 and then amended in February 2024.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.